SuperworthOmniAb price to book ratio OABI
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- 2.6×
- 4-year median
- 1.5×
- Against its 4-year history
- 98th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.6× to 2.7×
- Peer median
- 6.7×
OmniAb's price to book ratio is 2.6× as of Oct 23, 2026.
That is above its 4-year median of 1.5×, higher than on 98% of days in the last 4 years.
Over that time it ranged from 0.6× in May 2025 to 2.7× in Oct 2026.
The median for 6 diagnostics and research stocks of a similar size is 6.7×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.6× | 0.8× | 2.7× |
| 2025 | 1.0× | 0.6× | 1.6× |
| 2024 | 1.5× | 1.5× | 2.3× |
| 2023 | 2.2× | 1.2× | 2.2× |
Against its peers
Companies in Medical - Diagnostics & Research nearest OmniAb's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| OABIOmniAb | 2.6× |
| NRCNRC Health | 74.1× |
| CDNACareDx | 8.4× |
| VCYTVeracyte | 2.8× |
| ICCCImmucell | 3.0× |
| BLLNBillionToOne | 9.5× |
| LNTHLantheus | 5.0× |
| Peer median | 6.7× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on OmniAb
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.